Inventor · disambiguated record

Daniel Hicklin

Also filed as: HICKLIN DANIEL · HICKLIN DANIEL J

26 granted patents·30 pending applications·220 citations·filing 1994–2025

96Inventor score

Technology areasC07K A61K A61P G01N C12N

Files withWEREWOLF THERAPEUTICS INC23 POTENZA THERAPEUTICS INC9 NOVARTIS AG8 IMCLONE SYSTEMS INC5 TRIEZA THERAPEUTICS INC4

Top patents by PatentIndex Score

56 records

0198US10981990B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Apr 20, 2021·11 cites·30 claims
0298US9605070B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·67 cites·85 claims
0396US11352403B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Jun 7, 2022·6 cites·13 claims
0496US10696724B2Activatable interleukin-2 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·18 cites·11 claims
0595US11155620B2Method of detecting TIM-3 using antibody molecules to TIM-3NOVARTIS AG·Filed 2019·Granted Oct 26, 2021·6 cites·20 claims
0695US10696723B2Activatable interleukin 12 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·15 cites·12 claims
0794US11535658B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted Dec 27, 2022·2 cites·21 claims
0894US9713641B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2017·Granted Jul 25, 2017·35 cites·20 claims
0993US11981716B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted May 14, 2024·2 cites·13 claims
1093US10472419B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 12, 2019·12 cites·57 claims
1193US9884913B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Feb 6, 2018·12 cites·30 claims
1291US10232053B2Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancerTRIEZA THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·23 cites·5 claims
1383US10227413B2Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Mar 12, 2019·2 cites·20 claims
1482US10507244B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2017·Granted Dec 17, 2019·3 cites·24 claims
1582US2024358796A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
1682US2025213684A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2024·Application pending·0 cites
1781US11186644B2Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2019·Granted Nov 30, 2021·1 cites·11 claims
1879US12076371B2Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Granted Sep 3, 2024·0 cites·29 claims
1978US12275769B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Apr 15, 2025·0 cites·14 claims
2078US12036266B2Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Jul 16, 2024·0 cites·19 claims
2178US2024262880A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
2278US2022185883A1Method of detecting tim-3 using antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
2375US11739132B2Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Aug 29, 2023·0 cites·16 claims
2475US2024174725A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Application pending·0 cites
2574US2025179138A1Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2025·Application pending·0 cites
2674US2023272028A1Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Application pending·0 cites
2774US2023051423A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Application pending·0 cites
2870US11453710B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·0 cites·16 claims
2970US8143025B2Antibodies against vascular endothelial growth factor receptor-1WU YAN·Filed 2011·Granted Mar 27, 2012·1 cites·5 claims
3070US2022133889A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
3168US2022098312A1Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
3268US2021393803A1Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancerTRIEZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
3365US7371574B2Antibody antagonists of VE-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2002·Granted May 13, 2008·2 cites·11 claims
3465US2024216470A1Inducible il-2 and pd-1/pd-l1 combination therapyWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
3565US2024216505A1Inducible cytokine prodrug and pd-1/pd-l1 combination therapyWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
3665US2024216474A1Activatable interferon polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
3764US2021130430A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Application pending·0 cites
3862US2021115102A1Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Application pending·0 cites
3961US11590224B2Anti-TIGIT antigen-binding proteins and methods of uses thereofPOTENZA THERAPEUTICS INC·Filed 2019·Granted Feb 28, 2023·0 cites·8 claims
4061US2008311121A1Antibody antagonists of ve-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
4161US2008317750A1Antibody antagonists of ve-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
4261US2020014798A1Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancerTRIEZA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
4361US2009060909A1Antibody antagonists of ve-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
4460US2024043488A1Activatable il-12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Application pending·0 cites
4559US2024374687A1Il-2 prodrugWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
4658US2021269542A1Anti-gitr antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
4757US2023312715A1Constrained conditionally activated binding protein constructs with human serum albumin domainsTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
4856US2018207273A1Combination therapies comprising antibody molecules to tim-3DRANOFF GLENN·Filed 2016·Application pending·0 cites
4952US10988545B2Anti-GITR antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Apr 27, 2021·0 cites·11 claims
5052US2019142967A1Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of CancerTRIEZA THERAPEUTICS INC·Filed 2019·Application pending·0 cites

Showing the top 50 of 56 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Daniel Hicklin files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →